Current Report Filing (8-k)
September 29 2017 - 05:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
September
29, 2017
Commission File No. 000-16929
Soligenix, Inc.
(Exact name of small business issuer as
specified in its charter)
DELAWARE
|
|
41-1505029
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification Number)
|
|
|
|
29 Emmons Drive,
Suite C-10
Princeton, NJ
|
|
08540
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(609) 538-8200
|
(Issuer’s telephone number, including area code)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation
FD Disclosure.
Soligenix, Inc. (the
“Company”) has updated its corporate presentation (the “Presentation”) to include updates to the Presentation
since it was last included as an exhibit to the Company’s Form 8-K filed with the U.S. Securities and Exchange on June 8,
2017.
The Company updated
the Presentation to reflect the receipt of approximately $3.7 million in non-dilutive funding. The National Institutes of Health
(the “NIH”) awarded the Company approximately $1.5 million over two years to support the conduct of its pivotal Phase
3 clinical trial evaluating SGX301 (synthetic hypericin) as a treatment for cutaneous T-cell lymphoma. Further, the NIH granted
the Company an additional award of approximately $1.5 million over two years to support the conduct of its pivotal Phase 3 clinical
trial of SGX942 (dusquetide) as a treatment for severe oral mucositis in patients with head and neck cancer receiving chemoradiation
therapy. Finally, the Company will be participating in a grant awarded to the University of Hawai’i at Manoa for the development
of a thermostabilized Ebola vaccine, with the Company awarded funding of approximately $700,000 over five years.
Additionally, the Company
updated the estimated timeframe for the Phase 3 clinical trial of SGX301 development milestone, as its achievement may have the
potential to occur later in the year.
The slides from the
Presentation are attached hereto as Exhibit 99.1. The attached materials will be posted on the Company’s website
at www.soligenix.com. The Company does not undertake to update this Presentation.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Soligenix, Inc.
|
|
|
September 29, 2017
|
By:
|
/s/ Christopher J. Schaber
|
|
|
Christopher J. Schaber, Ph.D.
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
EXHIBIT INDEX
4
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Mar 2023 to Mar 2024